September 6, 2016 / 12:26 PM / a year ago

BRIEF-ProMetic announces the addition of tympanic membrane perforations to its plasminogen's targeted indications

1 Min Read

Sept 6 (Reuters) - ProMetic Life Sciences Inc

* Will be pursuing tympanic membrane perforations as one of its new plasma-derived plasminogen targeted clinical indications

* Expects to file its clinical trial application in Q4 2016

* Expects to initiate clinical trial in Sweden in patients suffering from chronic tympanic membrane perforations in H1 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below